Regeneron Pharmaceuticals, Inc. - 10-Q Summary
Business Context and Reporting Period
This filing covers the quarterly period ended June 30, 1999. Regeneron is a biotechnology company focused on discovering and developing novel therapeutics, including protein growth factors and small molecule drugs. Key programs include AXOKINE (for obesity/diabetes) in collaboration with Procter & Gamble, and BDNF/NT-3 (for ALS and constipation) via the Amgen-Regeneron Partners joint venture. The company has not yet generated revenue from commercial product sales.
Key Financial Metrics
| Metric | Three Months Ended June 30, 1999 | Six Months Ended June 30, 1999 |
|---|---|---|
| Total Revenues | $7.2 million | $14.1 million |
| Net Loss | ($7.8) million | ($16.8) million |
| Loss Per Share (Basic/Diluted) | ($0.25) | ($0.54) |
| Research & Development Expenses | $10.8 million | $22.0 million |
| Cash and Cash Equivalents | $20.6 million (as of June 30, 1999) | |
| Marketable Securities | ||
| Total Liquid Assets | $96.6 million (Cash + Marketable Securities) | |
| Accumulated Deficit | ($194.0) million (Cumulative since inception) |
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased 53% to $7.2 million in Q2 1999 from $15.2 million in Q2 1998. This was driven by a drop in contract research revenue (from $6.2M to $3.4M) due to the absence of a non-recurring $5.0 million milestone payment from Procter & Gamble received in 1998 and reduced activity from Sumitomo Pharmaceuticals.
- Expense Increase: Total operating expenses rose to $15.0 million in Q2 1999 from $13.1 million in Q2 1998. R&D expenses increased to $10.8 million due to higher staffing and clinical trial activity.
- Profitability Shift: The company reported a net loss of $7.8 million in Q2 1999, compared to a net income of $2.1 million in Q2 1998.
- Investment Loss: The loss attributable to the Amgen-Regeneron Partners joint venture increased to $0.6 million in Q2 1999 from $0.2 million in Q2 1998, reflecting increased clinical trial costs for BDNF and NT-3.
Outlook, Risks, and Management Commentary
- Liquidity: Management believes existing capital resources ($96.6 million in liquid assets) will meet operating needs for at least several years. No established lines of credit exist.
- Future Funding: The company expects Procter & Gamble research support to increase to at least $6.3 million per quarter starting in Q3 1999. Additional funding may be required for capital contributions to Amgen-Regeneron Partners.
- Clinical Progress: Phase I clinical trials for AXOKINE have commenced. BDNF trials for ALS are ongoing, including a new multi-center subcutaneous study starting August 1999.
- Year 2000 (Y2K) Risk: The company is not yet Y2K compliant. It estimates total remediation costs will be less than $1.0 million. Risks include potential power failures or equipment malfunctions affecting manufacturing and research.
- Intellectual Property: The company is involved in patent interference proceedings regarding CNTF/AXOKINE with Synergen (acquired by Amgen), though a covenant not to sue was signed in 1998.
Investor Verification Checklist
- Cash Burn Rate: Verify the sustainability of the $96.6 million cash position against the accelerating R&D spend and joint venture capital contribution requirements.
- Collaboration Reliance: Assess the risk of revenue concentration, as the majority of funding depends on the Procter & Gamble and Amgen agreements.
- Clinical Trial Outcomes: Monitor the safety and efficacy data from the AXOKINE Phase I trials and the BDNF ALS studies, as failure could materially impact future funding and valuation.
- Y2K Contingency: Confirm the implementation status of the Y2K contingency plan and the potential operational impact of power or equipment failures in early 2000.
- Patent Status: Review the final resolution of the CNTF patent interference to ensure no future royalty obligations or litigation risks remain.